Document 0998
 DOCN  M94A0998
 TI    Follow up of compound ELS to HIV/AIDS patients in Tanzania.
 DT    9412
 AU    Lugakingira ES; Barongo L; Katarama F; Kaswamila S; Traditional Medicine
       Unit Ukerewe.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):232 (abstract no. PB0941). Unique
       Identifier : AIDSLINE ICA10/94371577
 AB    OBJECTIVE: To make more studies determining the effectivity and
       tolerance by patients with HIV/AIDS. METHODS: For a period of six months
       from 1.1.1993 to 1.7.1993 thirty four more patients aged 2-40 years
       entered the study in addition to 256 old patients. They either gave oral
       or written consent prior to the study. They had clinical AIDS comfirmed
       by ELISA or Western blot. The compound's decoction was taken orally
       150mls three times per day to adults for 66 days consecutively and then
       for seven days per every month. Progress report was recorded by each
       patient or relative. RESULTS: In six months 34 patients (100%) were in
       stage 3. Thirty two patients (94%) showed clinical improvement and felt
       well; their symptoms improved, they gained weight. Only one patient
       reported drug reactions which included nausea, diarrhoea and mild
       headache. Two patients died while on treatment. The rest tolerated the
       drug very well. CONCLUSION: The extended studies revealed Compound ELS
       to be associated with improved quality of life with clearance of some
       opportunistic infections and enhancing of feeling well. Yet, further
       research is needed to assess the safety and active ingredients.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Adolescence  Adult
       Child  Child, Preschool  Human  Infant  Medicine, Traditional  Middle
       Age  CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).